

CMP: ₹ 2,750

Target: ₹ 3,315 (21%)

Target Period: 12 months

BUY

January 23, 2026

Performance continues to hinge on Chemicals...

About the stock: Incorporated in 1970, SRF started with Nylon Tyre Cord and thereafter diversified into refrigerant gas, speciality chemicals and packaging films.

- Chemical division accounts for 49% of the overall revenues followed by packaging film (36%), technical textile (12%) and others (3%).
- SRF will be incurring a capex of ~₹5,000 crore over the next 2-3 years to strengthen its fluorochemicals portfolio.

Investment Rationale

- Q3FY26- Chemicals Business drives growth-** Revenues grew 6% YoY to ₹3,611.5 crore driven by the Chemicals business (49% of the revenues) which reported a growth of 22% YoY to ₹1,825 crore. Meanwhile performance films (36% of revenues) declined by 3% YoY to ₹1,342 crore and Technical Textiles (12% of revenues) reported a decline of 11% YoY for the third consecutive quarter to ₹453 crore. Consolidated EBITDA stood at ₹780 crore, up 26% YoY, translating to margins of 21%, up ~330 bps YoY driven by the chemical business EBIT which stood at 27%, up ~300 bps YoY. PAT for the quarter stood at ₹432 crore, up 60% YoY.
- Robust Outlook for the fluorochemicals business** SRF's fluorochemicals business maintains a robust outlook, delivering decent volumes and healthy realizations even in a seasonally weak quarter, with its HFC plant operating at optimal utilization levels. Prices of R32 continued to hold firm with the quota driven economics (decreasing Chinese contribution) continued to favour prices. Looking ahead, the company is aggressively investing in the next-generation refrigerants, allocating ₹1,100 crore to add 10000 TPA of HFO (4th Gen refrigerant gas) capacity, with commercial revenue inflows expected to commence from FY28. Additionally, it plans an initial capex of ₹1,500-2,000 crore primarily targeted at further expanding HFO production capabilities in Odisha.
- Diversifying portfolio with Pharma and Advanced Fluoropolymers:** SRF is strategically diversifying its portfolio with a ₹180 crore capex to expand its pharma intermediates business, backed by a strong pipeline buildup, as the company targets doubling this segment's contribution from the current 10% to 20% of overall revenues over the next few years. Production under the Chemours partnership to supply value-added new fluoropolymers is likely to commence in CY26. These initiatives in pharma intermediates and advanced fluoropolymers are aimed at meaningfully reducing the company's dependency on the volatile agrochemicals business besides managing the weaknesses in Performance Films and Technical Textiles.

Rating and Target Price

- Our SoTP value is ₹3,315 based on 26x (Chemicals Business), 10x Performance films business and 5x Technical Textiles Business EBITDA.

Key Financial Summary

(₹ Crore)	FY23	FY24	FY25	5 year CAGR (FY20-25)		FY27E	FY28E	3 year CAGR (FY25-28E)
Net Revenue	14,870.3	13,138.5	12,433.7	11.5	15,783.1	17,516.6	20,234.0	17.6
EBITDA	3,529.2	2,584.1	2,718.4	13.3	3,509.7	4,016.4	4,823.1	21.1
EBITDA Margins (%)	23.7%	19.7%	21.9%		22.2%	22.9%	23.8%	
Adj.PAT	2,162.3	1,335.7	1,250.8	4.2	1,767.5	2,068.8	2,592.2	27.5
Adj. EPS (₹)	72.7	44.9	42.1		59.4	69.6	87.2	
EV/EBITDA	24.1x	33.3x	31.4x		24.5x	21.6x	18.0x	
P/E	21.6	61.2	65.4		46.3	39.5	31.6	
ROE (%)	20.94	11.64	9.91		12.72	13.38	14.76	
ROCE (%)	21.89	13.30	12.90		15.67	16.15	17.62	

Source: Company, ICICI Direct Research




Particulars

Particular	Amount
Market cap (₹ Crore)	87,943
FY25 Total Debt (₹ Crore)	4,726
FY23 Cash & Inv (₹ Crore)	354
EV (₹ Crore)	92,315
52 Week H/L	3325/ 2487
Equity Capital (₹ Crore)	297.4
Face Value (₹)	10

Shareholding pattern

in %	Mar-25	Jun-25	Sept-25	Dec-25
Promoter	50.3	50.3	50.3	50.3
DII	18.4	18.8	19.5	20.2
FII	18.3	18.2	18.0	17.5
Others	13.0	12.7	12.2	12.1

Price Chart



Key risks

- Lower than expected revenue growth in Fluro speciality business
- Continued softness in the speciality chemical business

Research Analyst

Siddhant Khandekar

Siddhant.khandekar@icicisecurities.com

Shubh Mehta

shubh.mehta@icicisecurities.com

Deep Thosani

deep.thosani@icicisecurities.com

Q3FY26 Earnings Release / Conference call highlights

Chemical Business-

- The segment performance improved on a YoY basis driven by higher volumes, despite deferment in demand by the Agro majors and continued pricing pressure from Chinese competitors.
- Fluorochemicals business delivered strong performance on account of higher volumes and realizations of HFCs in domestic and exports markets.
- Global prices for HFC remain firm due to China's quota- led supply restriction. Likewise, R32 export prices in China remain firm at USD 7/kg
- US markets remain cautious due to evolving tariff situation, resulting into lower annual contracts for HFCs.
- The management highlighted that it's unlikely to achieve FY26 revenue guidance of 20% for the speciality chemicals business.

Performance Films and Foils Business

- This segment reported a subdued quarter due to reduced volumes and rangebound pricing for BOPET and BOPP.
- GST 2.0 continued to impact the business as the companies were required to repack and reprint their products.
- The management highlighted that certain Chinese capacities in packaging films have shut which has started pushing up prices. Moreover, the company anticipates that more capacities may shut post Chinese New Year therefore, likely aiding recovery for the margins.
- Projects for capacitor grade film and BOPP lines are progressing as planned wherein the company had planned three projects: capacitor-grade film, PPPE film, and a new polypropylene film, with an aggregate capacity of 100,000-110,000 MT. The PP film for the capacitor grade under PLI scheme is the same as the previously announced capacitor-grade BOPP.

Technical Textiles

- This segment reported a weak performance due to Margin pressure in Belting Fabric (BF) due to Chinese imports
- Demand for Polyester Industrial Yarn (PIY) was soft due to prolonged monsoon.
- US import tariffs negatively impacted Belting Fabric, leading to increased imports from China at significantly lower prices.

Guidance:

- FY26 capital expenditure is expected to be ₹2,200-2,300 crore, including the Odisha land acquisition of ₹282 crore, which will cater to the entire chemicals business.
- SRF is adding 10000 tons capacity of HFO with total capex outlay of ₹1,100 crore; and expects the project to be commissioned in FY27 and revenue inflow from FY28.
- The company is adding a second pharma intermediate plant at an investment of ₹180 crore in Dahej. SRF aims to double contribution from pharma intermediate from 10% to 20% in next few years and eventually reduce its exposure to the agrochem business.
- The first stage of capex for the Odisha site will probably be in the range of ₹1,500- ₹2,000 crore.

Exhibit 1: Valuation Summary

Valuation - SoTP			
Particulars	FY28E EBITDA(₹ crore)	Multiple	EV
Chemical Business	3,571.0	26.0	92,847
Performance film	925.9	10.0	9,259.5
Technical Textiles	283.4	5.0	1,416.8
Net Debt (FY28E)			4,908.4
Implied Market Cap			98,614.5
No of Share (in crore)			29.7
Per share Value			3,315
Upside			21%

Source: Company, ICICI Direct Research

Financial Summary

Exhibit 2: Profit and loss statement				₹ crore
Year end March	FY25	FY26E	FY27E	FY28E
Total Operating Income	14,693.1	15,783.1	17,516.6	20,234.0
Growth (%)	11.8	7.4	11.0	15.5
Raw Material Expenses	7,699.2	7,575.9	8,320.4	9,510.0
Gross Profit	6,993.9	8,207.2	9,196.2	10,724.0
Employee Cost	1,042.5	1,104.8	1,226.2	1,416.4
Other Operating Expenses	3,233.0	3,592.7	3,953.6	4,484.5
EBITDA	2,718.4	3,509.7	4,016.4	4,823.1
Growth (%)	5.2	29.1	14.4	20.1
Other Income	132.7	50.8	57.1	93.3
EBITDA, including OI	2,851.2	3,560.5	4,073.5	4,916.4
Depreciation	771.5	820.3	928.4	1,038.3
Net Interest Exp.	376.0	383.5	386.8	421.8
Other exceptional items	0.0	0.0	0.0	0.0
PBT	1,703.7	2,356.6	2,758.4	3,456.3
Total Tax	452.9	589.2	689.6	864.1
Tax Rate	26.6%	25.0%	25.0%	25.0%
PAT	1,250.8	1,767.5	2,068.8	2,592.2
Adj.PAT after Minority interest	1,250.8	1,767.5	2,068.8	2,592.2
Adj. EPS (₹)	42.1	59.4	69.6	87.2
Shares Outstanding	29.7	29.7	29.7	29.7

Source: Company, ICICI Direct Research

Exhibit 3: Cash flow statement				₹ crore
Year end March	FY25	FY26E	FY27E	FY28E
PBT & Extraordinary	1,703.7	2,356.6	2,758.4	3,456.3
Depreciation	771.5	820.3	928.4	1,038.3
After other adjustments (Inc) / Dec in Working Capital	0.0	-342.4	-567.8	-551.2
Taxes	-333.9	-589.2	-689.6	-864.1
Others	346.2	383.5	386.8	421.8
CF from operating activities	2,487.5	2,628.9	2,816.1	3,501.1
Purchase of Fixed Assets	-1,222.3	-2,300.0	-2,800.0	-2,400.0
Others	-261.7	0.0	0.0	0.0
CF from investing activities	-1,484.0	-2,300.0	-2,800.0	-2,400.0
Proceeds from issue of shares	0.0	0.0	0.0	0.0
Borrowings (Net)	-429.1	500.0	600.0	400.0
Others	-641.4	-881.7	-885.0	-920.0
CF from financing activities	-1,070.5	-381.7	-285.0	-520.0
Net cash flow	-67.0	-52.8	-268.9	581.1
Effects of foreign currency translati	0.0	0.0	0.0	0.0
Opening Cash	407.5	353.8	300.9	32.0
Closing Cash	353.8	300.9	32.0	613.1

Source: Company, ICICI Direct Research

Exhibit 4: Balance Sheet				₹ crore
Year end March	FY25	FY26E	FY27E	FY28E
Liabilities				
Share Capital	297.4	297.4	297.4	297.4
Reserves	12,328.8	13,598.0	15,168.6	17,262.6
Total Shareholders Funds	12,626.2	13,895.5	15,466.0	17,560.0
Minority Interest	0.0	0.0	0.0	0.0
Long Term Borrowings	2,037.4	2,337.4	2,737.4	3,137.4
Net Deferred Tax liability	1,055.3	1,055.3	1,055.3	1,055.3
Other long term liabilities	325.7	99.6	110.6	127.7
Long term provisions	82.6	98.9	109.8	126.8
Current Liabilities and Provisions				
Short term borrowings	2,688.7	2,888.7	3,088.7	3,088.7
Trade Payables	2,331.6	2,810.7	3,119.4	3,603.3
Other Current Liabilities	399.9	439.6	487.8	563.5
Short Term Provisions	9.8	10.8	12.0	13.8
Total Current Liabilities	5,429.9	6,149.7	6,707.8	7,269.3
Total Liabilities	21,557.1	23,636.4	26,186.9	29,276.5
Assets				
Net Block	13,719.8	15,210.5	17,082.1	18,443.8
Capital Work in Progress	811.0	800.0	800.0	800.0
Intangible assets under devl.	0.0	0.0	0.0	0.0
Goodwill on Consolidation	0.0	0.0	0.0	0.0
Non-current investments	122.8	122.8	122.8	122.8
Deferred tax assets	35.7	35.7	35.7	35.7
Long term loans and advances	336.2	141.0	156.5	180.8
Other Non Current Assets	402.1	526.0	583.7	674.3
Current Assets, Loans & Advances				
Current Investments	704.5	704.5	704.5	704.5
Inventories	2,349.0	2,810.7	3,359.3	3,880.5
Sundry Debtors	2,169.5	2,378.3	2,639.5	3,049.0
Cash and Bank	353.8	300.9	32.0	613.1
Loans and Advances	17.1	17.1	17.1	17.1
Other Current assets	535.7	588.9	653.6	754.9
Current Assets	6,129.6	6,800.4	7,406.1	9,019.1
Total Assets	21,557.1	23,636.4	26,186.9	29,276.5

Source: Company, ICICI Direct Research

Exhibit 5: Key ratios				
Year end March	FY25	FY26E	FY27E	FY28E
<u>Per share data (₹)</u>				
Adj. EPS	42.1	59.4	69.6	87.2
Adj. Cash EPS	68.0	87.0	100.8	122.1
BV	424.5	467.2	520.0	590.4
DPS	16.8	16.8	16.8	16.8
<u>Operating Ratios (%)</u>				
Gross Margin (%)	47.6	52.0	52.5	53.0
EBITDA Margin (%)	18.5	22.2	22.9	23.8
PAT Margin (%)	8.5	11.2	11.8	12.8
Asset Turnover	1.2	1.3	1.3	1.3
Debtor Days	55	55	55	55
Inventory Days	60	65	70	70
Creditor Days	59	65	65	65
Cash Conversion Cycle	56	55	60	60
<u>Return Ratios (%)</u>				
Return on Assets (%)	5.8	7.5	7.9	8.9
RoCE (%)	12.9	15.7	16.1	17.6
Core RoC (%)	11.9	14.8	15.0	16.8
RoE (%)	9.9	12.7	13.4	14.8
<u>Solvency Ratios</u>				
Total Debt / Equity	0.4	0.4	0.4	0.4
Interest Coverage	5.5	7.1	8.1	9.2
Current Ratio	1.1	1.1	1.1	1.2
Quick Ratio	0.7	0.6	0.6	0.7
Debt/EBITDA	1.7	1.5	1.5	1.3
<u>Valuation Ratios (x)</u>				
EV/EBITDA	31.4	24.5	21.6	18.0
P/E	65.4	46.3	39.5	31.6
P/B	6.5	5.9	5.3	4.7
EV/Sales	5.8	5.4	5.0	4.3

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
Third Floor, Brillanto House,
Road No 13, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com

ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA; Shubh Mehta MBA (Tech); Deep Thosani, MBA; Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number - INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance Officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Jeetu Jawrani Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report